MNMatthew B. Neu

Matthew B. Neu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthew B. Neu has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Generational Placental Dysfunction in a Family with LHON Mitochondrial Disease

    by Solmaz Chamanara, Lekha Chilakamarri, Sophia M. Adelson, Grant S. Wells, Matthew Neu, Tia Moscarello, Sneha Goenka, John E. Gorzynski, Megan Grove, Euan A. Ashley, et al.

    Objectives: Leber hereditary optic neuropathy (LHON) is the most prevalent primary mitochondrial disease caused by disease-causing variants in the mitochondrial DNA. While affected individuals generally present with visual impairment, some individuals develop LHON Plus, a multisystem phenotype with other neurological and systemic manifestations. This report describes a family with MT-ND4-related LHON with an atypical presentation of placental dysfunction in affected females, all experiencing fetal or neonatal demise, suggesting a potential association between pathogenic variants in MT-ND4 and adverse pregnancy outcomes. ,Design: Case report.,Subject: A 16-year-old male with acute onset of painless, binocular vision loss was admitted for expedited subspeciality evaluation. Maternal family history was notable for several female relatives with pre-eclampsia; hemolysis, elevated liver enzymes, low platelets (HELLP syndrome), late-gestation pregnancy loss, and/or neonatal demise. ,Interventions: Comprehensive ophthalmologic, systemic, and neurological evaluations, neuroimaging, and ultra-rapid genome sequencing (urGS) including mtDNA were performed. ,Results: A maternally-inherited pathogenic homoplasmic MT-ND4 variant (m.11778G>A) was detected in the male proband and several of his maternal relatives.,Conclusions: The reproductive phenotypes of the affected females in this family with MT-ND4-related LHON support expanding the clinical spectrum of "LHON plus" to include placental dysfunction. The segregation of the familial pathogenic variant in MT-ND4 in affected females with adverse pregnancy outcomes supports the notion of mitochondrial dysfunction contributing to placental dysfunction and poor maternal and perinatal outcomes. This family highlights the importance of acquiring a detailed family and reproductive history in individuals with LHON, or other mitochondrial disease, as high-risk pregnancy monitoring may be warranted for female patients and affected female maternal relatives.,Keywords:,Leber hereditary optic neuropathy (LHON), MT-ND4, m.11778G>A, Mitochondrial DNA, Placental dysfunction, Adverse pregnancy outcomes.

  • Open Access

    MetaDome 2027: a comprehensively updated resource for aggregating missense variant evidence across homologous human protein domains

    by Laurens Wiel, Federico Ferraro, Jay Yu, Jimmy Zhen, Daniel Nachun, Rodrigo Mendez, Chloe M Reuter, Jason L Cui, Devon E Bonner, Jennefer N Carter, et al.

    The interpretation of missense variants remains a major challenge in clinical genetics. “Meta-domains” aggregate population and pathogenic variation across homologous Pfam domain instances in the human proteome, providing per-residue context for interpreting variants of uncertain significance (VUS). Our 2019 implementation, MetaDome, is widely used and named in clinical variant-classification guidelines. Here, we present the MetaDome 2027 update, featuring a comprehensively updated dataset and GRCh38 support. The redesigned pipeline enables incremental updates of GENCODE, UniProtKB/Swiss-Prot, Pfam, gnomAD, and ClinVar while maintaining 100% sequence-identity gene-to-protein mapping. Annotated Pfam domain instances grew 14.9% from 71 419 to 82 069 and meta-domain-eligible Pfam families (≥2 human occurrences) by 73.3% from 3334 to 5778; Pfam domains are annotated to 92% of human proteins. Approximately 43% of mapped protein-coding nucleotides (14.3 million in GRCh38, 13.8 million in GRCh37) are in a meta-domain; in GRCh38, 67.9% (37 692 of 55 548) of pathogenic or likely pathogenic ClinVar missense variants fall at such a position. We show how MetaDome helped reclassify a de novo missense VUS in RALA and identify 52 463 ClinVar missense VUS for which meta-domains supply otherwise unavailable pathogenic evidence. MetaDome is freely available at www.metadome.app.

  • Open Access

    MetaDome 2027: a comprehensively updated resource for aggregating missense variant evidence across homologous human protein domains

    by Laurens Wiel, Federico Ferraro, Jay Yu, Jimmy Zhen, Daniel Nachun, Rodrigo Mendez, Chloe M. Reuter, Jason L. Cui, Devon E. Bonner, Jennefer N. Carter, et al.

    The interpretation of missense variants remains a major challenge in clinical genetics. “Meta-domains” aggregate population and pathogenic variation across homologous Pfam domain instances in the human proteome, providing per-residue context for interpreting variants of uncertain significance (VUS). Our 2019 implementation, MetaDome, is widely used and named in clinical variant-classification guidelines. Here we present the MetaDome 2027 update, featuring a comprehensively updated dataset and GRCh38 support. The redesigned pipeline enables incremental updates of GENCODE, UniProtKB/Swiss-Prot, Pfam, gnomAD, and ClinVar while maintaining 100% sequence-identity gene-to-protein mapping. Annotated Pfam domain instances grew 14.9% from 71,419 to 82,069 and meta-domain-eligible Pfam families (≥2 human occurrences) by 73.3% from 3,334 to 5,778; Pfam domains are annotated to 92% of human proteins. Approximately 43% of mapped protein-coding nucleotides (14.3 million in GRCh38, 13.8 million in GRCh37) are in a meta-domain; in GRCh38 67.9% (37,692 of 55,548) of pathogenic or likely pathogenic ClinVar missense variants fall at such a position. We show how MetaDome helped reclassify a de novo missense VUS in RALA and identify 52,463 ClinVar missense VUS for which meta-domains supply otherwise unavailable pathogenic evidence. MetaDome is freely available at www.metadome.app . Graphical


  • De Novo Variants Associated With Autosomal Recessive Conditions: Case Series and Implications for Genetic Testing and Counseling

    by Annie D. Niehaus, Devon E. Bonner, Jennefer Carter, Kayleigh Avello, Natalie Jacob, Matthew B. Neu, Rodrigo Mendez, Wanqiong Qiao, Stuart A. Scott, Rebecca J. Levy, et al.

    The vast majority of individuals with autosomal recessive ( AR ) conditions demonstrate biparental inheritance of the disease‐causing alleles; however, de novo variants also contribute to AR disease. This report represents the largest cohort to‐date of rare AR conditions in which one of the disease‐causing alleles was inherited and one occurred de novo. Clinical and research staff at Stanford University, clinical sites of the Undiagnosed Diseases Network ( UDN ) and Genomics Research to Elucidate the Genetics of Rare diseases ( GREGoR ) Consortium, and a large clinical genetic testing laboratory were contacted to identify cases of an AR diagnosis resulting from an inherited and de novo disease‐causing variant in trans. Fifteen cases of AR conditions caused by one inherited and one de novo variant in a gene consistent with the clinical phenotype were identified; all had undergone trio exome or genome sequencing with genetic confirmation of reported relationships. Variants were confirmed to be in trans in eight of the 15 cases. The de novo variant was confirmed ( n = 7) or presumed ( n = 7) to have arisen on the paternal allele in 14/15 (93%) of cases. Phenotypic and/or molecular evidence of an AR condition should prompt parental segregation analysis to inform diagnosis, recurrence risks, and variant classification. Additional studies are needed to determine the incidence of this phenomenon given the implications for the interpretation of genetic testing and counseling for AR conditions.

  • Open Access

    De novo mutations in the GTP/GDP-binding region of RALA, a RAS-like small GTPase, cause intellectual disability and developmental delay

    by Susan M Hiatt, Matthew B Neu, Ryne C Ramaker, Andrew A Hardigan, Jeremy W Prokop, Miroslava Hancarova, Darina Prchalova, Marketa Havlovicova, Jan Prchal, Viktor Stranecky, et al.

    Mutations that alter signaling of RAS/MAPK-family proteins give rise to a group of Mendelian diseases known as RASopathies. However, among RASopathies, the matrix of genotype-phenotype relationships is still incomplete, in part because there are many RAS-related proteins and in part because the phenotypic consequences may be variable and/or pleiotropic. Here, we describe a cohort of ten cases, drawn from six clinical sites and over 16,000 sequenced probands, with de novo protein-altering variation in RALA, a RAS-like small GTPase. All probands present with speech and motor delays, and most have intellectual disability, low weight, short stature, and facial dysmorphism. The observed rate of de novo RALA variants in affected probands is significantly higher (p = 4.93 x 10−11) than expected from the estimated random mutation rate. Further, all de novo variants described here affect residues within the GTP/GDP-binding region of RALA; in fact, six alleles arose at only two codons, Val25 and Lys128. The affected residues are highly conserved across both RAL- and RAS-family genes, are devoid of variation in large human population datasets, and several are homologous to positions at which disease-associated variants have been observed in other GTPase genes. We directly assayed GTP hydrolysis and RALA effector-protein binding of the observed variants, and found that all but one tested variant significantly reduced both activities compared to wild-type. The one exception, S157A, reduced GTP hydrolysis but significantly increased RALA-effector binding, an observation similar to that seen for oncogenic RAS variants. These results show the power of data sharing for the interpretation and analysis of rare variation, expand the spectrum of molecular causes of developmental disability to include RALA, and provide additional insight into the pathogenesis of human disease caused by mutations in small GTPases. While many causes of developmental disabilities have been identified, a large number of affected children cannot be diagnosed despite extensive medical testing. Previously unknown genetic factors are likely to be the culprits in many of these cases. Using DNA sequencing, and by sharing information among many doctors and researchers, we have identified a set of individuals with developmental problems who all have changes to the same gene, RALA. The affected individuals all have similar symptoms, including intellectual disability, speech delay (or no speech), and problems with motor skills like walking. In nearly all of these cases (10 of 11), the genetic change found in the child was not inherited from either parent. The locations and biological properties of these changes suggest that they are likely to disrupt the normal functions of RALA. Functional experiments also show that the genetic changes found in these individuals alter two key functions of RALA. Together, we have provided evidence that genetic changes in RALA can cause developmental disabilities. These results will allow doctors and researchers to identify additional children with the same condition, providing a clinical diagnosis to these families and leading to new research opportunities.